Second Genome’s New IBD Drug Advances To Phase 1 Trial

Second Genome’s New IBD Drug Advances To Phase 1 Trial
second genome squareSecond Genome Inc. recently advanced SGM-1019, the company's primary microbiome drug indicated for inflammatory bowel disease (IBD), to Phase 1 clinical testing to identify an optimal dose. Peter DiLaura, President and the CEO of the company, said in a press release: “Our scientists have identified a novel and important relationship between microbiome modulation of the target of SGM-1019 and IBD. SGM-1019 has the potential to address a critical unmet need in [IBD] treatment as a safe and well-tolerated oral therapy with an important disease modifying effect.” SGM-1019 was previously assessed in a placebo controlled, double-blinded, single ascending oral dose study. The targeted exposure levels were reached and strong activity was demonstrated against an identified IBD contributing factor. SGM-1019 was not reported to cause any serious adverse effects. Researchers have not revealed the name of SGM-1019's target, but disclosed it was discovered through the company’s Microbiome Discovery Platform. “Second Genome is focused on efficie
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *